Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules as Enhancers of Bone Formation in Bone Grafting

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age35+
SponsorPontificia Universidade Católica do Rio Grande do Sul

About this trial

This study aims to evaluate bone formation in grafts in terms of its quality (density), quantity (volume) and maturation obtained with the application of a tissue-engineered bone grafting compound containing concentrated autogenous cell-culture medium (CM) and a synthetic bone substitute. The present study was designed as an experimental prospective split-mouth randomized controlled clinical trial. After protocol approval by the Research Ethics Committee, a total of 20 consecutive participants in need of maxillary reconstruction aiming implant-supported oral rehabilitation will be invited to join the study. To collect autogenous adipose tissue-derived mesenchymal stem cells (hASCs), an outpatient lipoplasty procedure at the abdominal area of each patient will be performed. To isolate and expand hASCs from the lipoaspirate, specific cell culture protocols will be followed, resulting in cultured viable cells and their conditioned medium (CM). Cells and CM will be then separated by a sequence of filters and centrifugation, and isolated CM will be frozen. ELISA will analyze the presence of chemokines and their concentration in CM before grafting. Following pre-op surgical planning, both maxillary sinuses of each patient will be grafted internally applying a lateral window to each sinus. The bony floor of the test maxillary sinus will be augmented with synthetic bone substitute (BoneCeramic™ 1-2 mm) mixed with 10 to 15 ml of CM (test). The control site will receive bone substitute with saline. Lateral windows in both sinuses will be then closed with a collagen membrane (Bio-Gide™). After 6 months, first-stage implant surgery will be performed placing 6 implants in each patient. Registration of implant stability by manual torque wrench will be performed. Also, bone biopsies from each drilled implant site will be collected for histology, histomorphometry and immunohistochemistry (RT-PCR). Tomographic evaluation of the bone formation will include cone beam computed tomographies (CBCTs) at pre-operative \[Baseline\], 90 \[T1\] and 180 \[T2 = implant placement\] days for bone 3D image analysis.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

patients >35 years-old.

presenting highly atrophic fully edentulous maxilla (residual bone height <5 mm).

In need of bilateral sinus floor augmentation aiming full mouth implant-supported rehabilitation.

having teeth extraction at least 8 weeks prior to bone augmentation.

Disqualifiers

smokers, illicit drug users and alcohol daily consumers.

patients with metabolic and/or systemic diseases leading to impaired healing (e.g. decompensated diabetes, leukocyte or coagulation disorders, immunosuppression).

history of radiotherapy in the head or neck region.

bisphosphonate-based therapy recipients.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Maxillary sinus floor elevation grafting with synthetic bone substitute.

    Procedure/Surgery

    Bone augmentation at the floor of the maxillary sinus with bone substitutes.

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: Control (conventional graft procedure), bone substitute and saline solution.Placebo comparator 1 intervention
Group B: Test (modified graft), bone substitute and concentrated culture medium (CM)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Assessment of changes in bone density and quantity

Comparative analysis (test vs. control) of the changes in bone density and quantity by cone beam computed tomography (CBCT).

Time frame
0 (baseline), 90 and 180 days
2

Assessment of bone quantity

Histomorphometry analysis expressed in percentage of newly formed bone

Time frame
180 days

Secondary outcomes

1

Presence of bone formation markers

RT-PCR assessing specific bone formation markers

Time frame
180 days

Other outcomes

1

Assessment of bone substitute resorption rate

Resorption rate of bone substitute particles (test vs.control) compared by histologic analysis and histomorphometric analyses.

Time frame
180 days

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Pontificia Universidade Católica do Rio Grande do Sul

Lead sponsor

ITI International Team for Implantology, Switzerland

Collaborator

KU Leuven

Collaborator

Rio Grande do Sul Brain Institute (InsCer)

Collaborator

This trial is not recruiting at the moment. You can still explore other options: